Dr. Larson on Immunotherapy for Colorectal Cancer

Tim G. Larson, MD
Published: Monday, Sep 25, 2017



Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Immunotherapies have seen success in patients with microsatellite instability-high (MSI-H) CRC even though this only includes a small percentage of patients, states Larson. Patients with microsatellite stable (MSS) CRC have not seen the same results but this is under current investigation since they make up 95% of the patient population.

Unique combinations or molecules might show some signs of progress for these patients, explains Larson.
 


Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Immunotherapies have seen success in patients with microsatellite instability-high (MSI-H) CRC even though this only includes a small percentage of patients, states Larson. Patients with microsatellite stable (MSS) CRC have not seen the same results but this is under current investigation since they make up 95% of the patient population.

Unique combinations or molecules might show some signs of progress for these patients, explains Larson.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x